Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Trial Profile

Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 03 Jul 2018 Planned End Date changed from 15 Jun 2020 to 14 Jun 2021.
    • 03 Jul 2018 Planned primary completion date changed from 31 May 2020 to 15 Jun 2020.
    • 03 Jul 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top